Roche vis set to acquire Carmot Therapeutics, along with three clinical-stage assets for treating obesity and diabetes, for €2.85 billion.
Michael Jermaine Cards is a journalist who writes for Born2Invest, covering a wide range of topics in the business and pharmaceutical industries. With a focus on financial news and investments, Michael provides insightful analysis and reporting on the latest developments in the pharmaceutical sector, including mergers and acquisitions, drug approvals, and market trends.